Our top pick for
EDAP TMS S.A is a medical devices business based in the US. EDAP TMS S-A shares (EDAP) are listed on the NASDAQ and all prices are listed in US Dollars. EDAP TMS S-A employs 223 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.07|
|52-week range||$3.85 - $10.68|
|50-day moving average||$6.14|
|200-day moving average||$6.64|
|Wall St. target price||$13.30|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.00|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||0.33%|
|1 month (2021-09-22)||-2.88%|
|3 months (2021-07-22)||-0.16%|
|6 months (2021-04-22)||-28.17%|
|1 year (2020-10-22)||30.96%|
|2 years (2019-10-22)||22.13%|
|3 years (2018-10-22)||110.76%|
|5 years (2016-10-21)||123.16%|
Valuing EDAP TMS S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of EDAP TMS S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
EDAP TMS S-A's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6050x. In other words, EDAP TMS S-A shares trade at around 6050x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
EDAP TMS S-A's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 90.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into EDAP TMS S-A's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
EDAP TMS S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4 million.
The EBITDA is a measure of a EDAP TMS S-A's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$45.5 million|
|Operating margin TTM||3.83%|
|Gross profit TTM||$18.4 million|
|Return on assets TTM||0.89%|
|Return on equity TTM||1.39%|
|Market capitalisation||$201.7 million|
TTM: trailing 12 months
There are currently 93,464 EDAP TMS S-A shares held short by investors – that's known as EDAP TMS S-A's "short interest". This figure is 91.6% up from 48,792 last month.
There are a few different ways that this level of interest in shorting EDAP TMS S-A shares can be evaluated.
EDAP TMS S-A's "short interest ratio" (SIR) is the quantity of EDAP TMS S-A shares currently shorted divided by the average quantity of EDAP TMS S-A shares traded daily (recently around 101591.30434783). EDAP TMS S-A's SIR currently stands at 0.92. In other words for every 100,000 EDAP TMS S-A shares traded daily on the market, roughly 920 shares are currently held short.
However EDAP TMS S-A's short interest can also be evaluated against the total number of EDAP TMS S-A shares, or, against the total number of tradable EDAP TMS S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EDAP TMS S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 EDAP TMS S-A shares in existence, roughly 0 shares are currently held short) or 0.0031% of the tradable shares (for every 100,000 tradable EDAP TMS S-A shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against EDAP TMS S-A.
Find out more about how you can short EDAP TMS S-A stock.
We're not expecting EDAP TMS S-A to pay a dividend over the next 12 months.
Over the last 12 months, EDAP TMS S-A's shares have ranged in value from as little as $3.85 up to $10.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EDAP TMS S-A's is 1.654. This would suggest that EDAP TMS S-A's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
EDAP TMS S. A. , together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three divisions: High Intensity Focused Ultrasound (HIFU); Extracorporeal ShockWave Lithotripsy (ESWL); and Distribution. The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.